Sweden questions cancer diagnosis information management
This article was originally published in Clinica
The transfer of information from doctor to patient in Sweden after cancer diagnosis must be improved. This is one of the conclusions drawn in a report entitled "Cancer within the healthcare chain", commissioned by the Uppsala-Orebro regional working group of the Swedish National Board of Health and Welfare (SOS).
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.